From neurodevelopment to neurodegeneration: The interaction of neurofibromin and valosin-containing protein/p97 in regulation of dendritic spine formation

Journal of Biomedical Science

Volumn 19, Issue 1, 2012, Pages

  Hsueh, Yi Ping ^a  

^a INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

Author keywords

Dendritic spine formation; IBMPFD; Neurodevelopmental disorder; Neurofibromatosis Type I; neurofibromin; statin; VCP p97

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEUROFIBROMIN; VALOSIN CONTAINING PROTEIN; ADENOSINE TRIPHOSPHATASE; CDC48 PROTEIN; CELL CYCLE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE;

AUTOSOMAL DOMINANT DISORDER; BONE METABOLISM; BRAIN FUNCTION; CELL GROWTH; CHOLESTEROL SYNTHESIS; DEGENERATIVE DISEASE; DENDRITIC SPINE; ENZYME ACTIVITY; ENZYME INHIBITION; FRONTOTEMPORAL DEMENTIA; GENETIC DISORDER; GROWTH REGULATION; HUMAN; LEARNING DISORDER; LIPID METABOLISM; MORPHOGENESIS; NERVOUS SYSTEM DEVELOPMENT; NEUROFIBROMATOSIS; NONHUMAN; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; CONTRACTURE; GENETICS; INCLUSION BODY MYOSITIS; METABOLISM; NERVE CELL; OPHTHALMOPLEGIA; PATHOLOGY;

ADENOSINE TRIPHOSPHATASES; CELL CYCLE PROTEINS; CONTRACTURE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DENDRITIC SPINES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; METABOLIC NETWORKS AND PATHWAYS; MORPHOGENESIS; MYOSITIS, INCLUSION BODY; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; NEURONS; OPHTHALMOPLEGIA;

EID: 84858731267     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-19-33     Document Type: Review

References (84)

1. Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics. Harris KM, Stevens JK, J Neurosci 1989 9 2982 2997 2769375 (Pubitemid 19214329)
2. Reversing neurodevelopmental disorders in adults. Ehninger D, Li W, Fox K, Stryker MP, Silva AJ, Neuron 2008 60 950 960 10.1016/j.neuron.2008.12.007 19109903
3. Failure of neuronal homeostasis results in common neuropsychiatric phenotypes. Ramocki MB, Zoghbi HY, Nature 2008 455 912 918 10.1038/nature07457 18923513
4. Synaptic deficits are rescued in the p25/Cdk5 model of neurodegeneration by the reduction of beta-secretase (BACE1). Giusti-Rodriguez P, Gao J, Graff J, Rei D, Soda T, Tsai LH, J Neurosci 2011 31 15751 15756 10.1523/JNEUROSCI.3588- 11.2011 22049418
5. The Abeta oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Ferreira ST, Klein WL, Neurobiol Learn Mem 2011 96 529 543 10.1016/j.nlm.2011.08.003 21914486
6. Spines, plasticity, and cognition in Alzheimer's model mice. Spires-Jones T, Knafo S, Neural Plast 2012 2012 319836 22203915
7. Syndecan-2 induces filopodia formation via the neurofibromin-PKA-Ena/VASP pathway. Lin Y-L, Lei Y-T, Hong C-J, Hsueh YP, J Cell Biol 2007 177 829 841 10.1083/jcb.200608121 17548511 (Pubitemid 46873089)
8. Valosin-containing protein and neurofibromin interact to regulate dendritic spine density. Wang HF, Shih YT, Chen CY, Chao HW, Lee MJ, Hsueh YP, J Clin Invest 2011 121 4820 4837 10.1172/JCI45677 22105171
9. Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors. Upadhyaya M, Front Biosci 2011 16 937 951 10.2741/3727 21196210
10. Genetically engineered mouse models shed new light on the pathogenesis of neurofibromatosis type I-related neoplasms of the peripheral nervous system. Brossier NM, Carroll SL, Brain Res Bull 2011 10.1016/j.brainresbull.2011.08.005 [doi]
11. p97-containing complexes in proliferation control and cancer: emerging culprits or guilt by association? Haines DS, Genes Cancer 2010 1 753 763 10.1177/1947601910381381 21103003
12. Pathogenesis of Paget's disease of bone. Ralston SH, Bone 2008 43 819 825 10.1016/j.bone.2008.06.015 18672105
13. Recent insights into bone development, homeostasis, and repair in type 1 neurofibromatosis (NF1). Schindeler A, Little DG, Bone 2008 42 616 622 10.1016/j.bone.2007.11.006 18248783
14. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Costa RM, Federov NB, Kogan JH, Murphy GG, Stern J, Ohno M, Kucherlapati R, Jacks T, Silva AJ, Nature 2002 415 526 530 10.1038/nature711 11793011 (Pubitemid 34130607)
15. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Hyman SL, Shores A, North KN, Neurology 2005 65 1037 1044 10.1212/01.wnl.0000179303.72345.ce 16217056 (Pubitemid 41429628)
16. Learning disabilities in children with neurofibromatosis type 1: subtypes, cognitive profile, and attention-deficit-hyperactivity disorder. Hyman SL, Arthur Shores E, North KN, Dev Med Child Neurol 2006 48 973 977 10.1017/S0012162206002131 17109785 (Pubitemid 44768799)
17. Association study of the NF1 gene and autistic disorder. Mbarek O, Marouillat S, Martineau J, Barthelemy C, Muh JP, Andres C, Am J Med Genet 1999 88 729 732 10.1002/(SICI)1096-8628(19991215)88:6<729::AID-AJMG26>3.0.CO;2- Q 10581497
18. Association between the neurofibromatosis-1 (NF1) locus and autism in the Japanese population. Marui T, Hashimoto O, Nanba E, Kato C, Tochigi M, Umekage T, Ishijima M, Kohda K, Kato N, Sasaki T, Am J Med Genet B Neuropsychiatr Genet 2004 131B 43 47 10.1002/ajmg.b.20119 15389774 (Pubitemid 39458436)
19. Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, Peltonen J, Osteoporos Int 2005 16 928 936 10.1007/s00198-004-1801-4 15551055 (Pubitemid 41127102)
20. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Easton DF, Ponder MA, Huson SM, Ponder BA, Am J Hum Genet 1993 53 305 313 8328449 (Pubitemid 23308924)
21. Associations of clinical features in neurofibromatosis 1 (NF1). Szudek J, Birch P, Riccardi VM, Evans DG, Friedman JM, Genet Epidemiol 2000 19 429 439 10.1002/1098-2272(200012)19:4<429::AID-GEPI13>3.0.CO;2-N 11108651
22. The neurofibromatosis type 1 gene encodes a protein related to GAP. Xu GF, O'Connell P, Viskochil D, Cawthon R, Robertson M, Culver M, Dunn D, Stevens J, Gesteland R, White R, et al. Cell 1990 62 599 608 10.1016/0092-8674(90)90024- 9 2116237 (Pubitemid 20263229)
23. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Brannan CI, Perkins AS, Vogel KS, Ratner N, Nordlund ML, Reid SW, Buchberg AM, Jenkins NA, Parada LF, Copeland NG, Genes Dev 1994 8 1019 1029 10.1101/gad.8.9.1019 7926784 (Pubitemid 24145666)
24. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA, Nat Genet 1994 7 353 361 10.1038/ng0794-353 7920653 (Pubitemid 24204410)
25. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Xu GF, Lin B, Tanaka K, Dunn D, Wood D, Gesteland R, White R, Weiss R, Tamanoi F, Cell 1990 63 835 841 10.1016/0092-8674(90)90149-9 2121369 (Pubitemid 120035056)
26. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Ballester R, Marchuk D, Boguski M, Saulino A, Letcher R, Wigler M, Collins F, Cell 1990 63 851 859 10.1016/0092-8674(90)90151-4 2121371 (Pubitemid 120035058)
27. The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Martin GA, Viskochil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O'Connell P, Cawthon RM, et al. Cell 1990 63 843 849 10.1016/0092-8674(90)90150-D 2121370 (Pubitemid 120035057)
28. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Guo HF, The I, Hannan F, Bernards A, Zhong Y, Science 1997 276 795 798 10.1126/science.276.5313.795 9115204 (Pubitemid 27199859)
29. Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. Hannan F, Ho I, Tong JJ, Zhu Y, Nurnberg P, Zhong Y, Hum Mol Genet 2006 15 1087 1098 10.1093/hmg/ddl023 16513807
30. Neurofibromin signaling and synapses. Hsueh YP, J Biomed Sci 2007 14 461 466 10.1007/s11373-007-9158-2 17370141 (Pubitemid 47063480)
31. A neurofibromatosis-1-regulated pathway is required for learning in Drosophila. Guo HF, Tong J, Hannan F, Luo L, Zhong Y, Nature 2000 403 895 898 10.1038/35002593 10706287 (Pubitemid 30130991)
32. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Tong J, Hannan F, Zhu Y, Bernards A, Zhong Y, Nat Neurosci 2002 5 95 96 10.1038/nn792 11788835 (Pubitemid 34121572)
33. Neurofibromin physically interacts with the N-terminal domain of focal adhesion kinase. Kweh F, Zheng M, Kurenova E, Wallace M, Golubovskaya V, Cance WG, Mol Carcinog 2009 48 1005 1017 10.1002/mc.20552 19479903
34. Bipartite interaction between neurofibromatosis type I protein (neurofibromin) and syndecan transmembrane heparan sulfate proteoglycans. Hsueh YP, Roberts AM, Volta M, Sheng M, Roberts RG, J Neurosci 2001 21 3764 3770 11356864 (Pubitemid 32466468)
35. Neurofibromin interacts with CRMP-2 and CRMP-4 in rat brain. Lin YL, Hsueh YP, Biochem Biophys Res Commun 2008 369 747 752 10.1016/j.bbrc.2008.02.095 18313395
36. Characterisation of the interaction between syndecan-2, neurofibromin and CASK: dependence of interaction on syndecan dimerization. Volta M, Calza S, Roberts AM, Roberts RG, Biochem Biophys Res Commun 2010 391 1216 1221 10.1016/j.bbrc.2009.12.043 20006588
37. Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes. De Schepper S, Boucneau JM, Westbroek W, Mommaas M, Onderwater J, Messiaen L, Naeyaert JM, Lambert JL, J Invest Dermatol 2006 126 653 659 10.1038/sj.jid.5700087 16374483 (Pubitemid 43255656)
38. PKA phosphorylation and 14-3-3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin. Feng L, Yunoue S, Tokuo H, Ozawa T, Zhang D, Patrakitkomjorn S, Ichimura T, Saya H, Araki N, FEBS Lett 2004 557 275 282 10.1016/S0014-5793(03)01507-2 14741381 (Pubitemid 38115909)
39. Neurofibromatosis type 1 (NF1) tumor suppressor, neurofibromin, regulates the neuronal differentiation of PC12 cells via its associating protein, CRMP-2. Patrakitkomjorn S, Kobayashi D, Morikawa T, Wilson MM, Tsubota N, Irie A, Ozawa T, Aoki M, Arimura N, Kaibuchi K, Saya H, Araki N, J Biol Chem 2008 283 9399 9413 10.1074/jbc.M708206200 18218617
40. A novel bipartite phospholipid-binding module in the neurofibromatosis type 1 protein. D'Angelo I, Welti S, Bonneau F, Scheffzek K, EMBO Rep 2006 7 174 179 10.1038/sj.embor.7400602 16397625
41. The sec14 homology module of neurofibromin binds cellular glycerophospholipids: mass spectrometry and structure of a lipid complex. Welti S, Fraterman S, D'Angelo I, Wilm M, Scheffzek K, J Mol Biol 2007 366 551 562 10.1016/j.jmb.2006.11.055 17187824 (Pubitemid 46136212)
42. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, Pestronk A, Whyte MP, Kimonis VE, Nat Genet 2004 36 377 381 10.1038/ng1332 15034582 (Pubitemid 38437260)
43. Another VCP interactor: NF is enough. Weihl CC, J Clin Invest 2011 121 4627 4630 10.1172/JCI61126 22105166
44. Valosin containing protein associated fronto-temporal lobar degeneration: clinical presentation, pathologic features and pathogenesis. Weihl CC, Curr Alzheimer Res 2011 8 252 260 10.2174/156720511795563773 21222596
45. Borghero Get al.: Exome sequencing reveals VCP mutations as a cause of familial ALS. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, Gibbs JR, Brunetti M, Gronka S, Wuu J, Ding J, McCluskey L, Martinez-Lage M, Falcone D, Hernandez DG, Arepalli S, Chong S, Schymick JC, Rothstein J, Landi F, Wang YD, Calvo A, Mora G, Sabatelli M, Monsurro MR, Battistini S, Salvi F, Spataro R, Sola P, Neuron 2010 68 857 864 10.1016/j.neuron.2010.11.036 21145000
46. VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Hirabayashi M, Inoue K, Tanaka K, Nakadate K, Ohsawa Y, Kamei Y, Popiel AH, Sinohara A, Iwamatsu A, Kimura Y, Uchiyama Y, Hori S, Kakizuka A, Cell Death Differ 2001 8 977 984 10.1038/sj.cdd.4400907 11598795 (Pubitemid 32994648)
47. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD, Taylor JP, Kretzschmar HA, Kimonis VE, Forman MS, J Neuropathol Exp Neurol 2007 66 152 157 10.1097/nen.0b013e31803020b9 17279000 (Pubitemid 46208736)
48. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A, J Neurol Neurosurg Psychiatry 2008 79 1186 1189 10.1136/jnnp.2007.131334 18796596
49. TDP-43 mediates degeneration in a novel Drosophila model of disease caused by mutations in VCP/p97. Ritson GP, Custer SK, Freibaum BD, Guinto JB, Geffel D, Moore J, Tang W, Winton MJ, Neumann M, Trojanowski JQ, Lee VM, Forman MS, Taylor JP, J Neurosci 2010 30 7729 7739 10.1523/JNEUROSCI.5894-09.2010 20519548
50. NSF and p97/VCP: similar at first, different at last. Brunger AT, DeLaBarre B, FEBS Lett 2003 555 126 133 10.1016/S0014-5793(03)01107-4 14630332 (Pubitemid 37431109)
51. Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. Wang Q, Song C, Li CC, J Struct Biol 2004 146 44 57 10.1016/j.jsb.2003.11.014 15037236 (Pubitemid 38369017)
52. Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle. Rouiller I, DeLaBarre B, May AP, Weis WI, Brunger AT, Milligan RA, Wilson-Kubalek EM, Nat Struct Biol 2002 9 950 957 10.1038/nsb872 12434150 (Pubitemid 35417066)
53. A novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants. Tang WK, Li D, Li CC, Esser L, Dai R, Guo L, Xia D, EMBO J 2010 29 2217 2229 10.1038/emboj.2010.104 20512113
54. Mutant valosin-containing protein causes a novel type of frontotemporal dementia. Schroder R, Watts GD, Mehta SG, Evert BO, Broich P, Fliessbach K, Pauls K, Hans VH, Kimonis V, Thal DR, Ann Neurol 2005 57 457 461 10.1002/ana.20407 15732117 (Pubitemid 40343972)
55. Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia. Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, Neilan EG, Kartashov A, Forman MS, Tucker S, Kimonis K, Mumm S, Whyte MP, Smith CD, Watts GD, Am J Med Genet A 2008 146 745 757 (Pubitemid 351354150)
56. Hereditary inclusion body myopathy-linked p97/VCP mutations in the NH2 domain and the D1 ring modulate p97/VCP ATPase activity and D2 ring conformation. Halawani D, LeBlanc AC, Rouiller I, Michnick SW, Servant MJ, Latterich M, Mol Cell Biol 2009 29 4484 4494 10.1128/MCB.00252-09 19506019
57. AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential. Vij N, J Cell Mol Med 2008 12 2511 2518 10.1111/j.1582-4934.2008. 00462.x 18798739
58. Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48. Jarosch E, Taxis C, Volkwein C, Bordallo J, Finley D, Wolf DH, Sommer T, Nat Cell Biol 2002 4 134 139 10.1038/ncb746 11813000 (Pubitemid 34141479)
59. Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47. Dreveny I, Kondo H, Uchiyama K, Shaw A, Zhang X, Freemont PS, EMBO J 2004 23 1030 1039 10.1038/sj.emboj.7600139 14988733 (Pubitemid 38436868)
60. ER stress and diseases. Yoshida H, FEBS J 2007 274 630 658 10.1111/j.1742-4658.2007.05639.x 17288551 (Pubitemid 46150855)
61. p97/p47-Mediated biogenesis of Golgi and ER. Uchiyama K, Kondo H, J Biochem 2005 137 115 119 10.1093/jb/mvi028 15749824
62. p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system. Ju JS, Weihl CC, Autophagy 2010 6 283 285 10.4161/auto.6.2.11063 20083896
63. VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD. Tresse E, Salomons FA, Vesa J, Bott LC, Kimonis V, Yao TP, Dantuma NP, Taylor JP, Autophagy 2010 6 217 227 10.4161/auto.6.2.11014 20104022
64. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Meyer H, Bug M, Bremer S, Nat Cell Biol 2012 14 117 123 10.1038/ncb2407 22298039
65. Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. Weihl CC, Dalal S, Pestronk A, Hanson PI, Hum Mol Genet 2006 15 189 199 16321991 (Pubitemid 43125974)
66. Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease. Ju JS, Fuentealba RA, Miller SE, Jackson E, Piwnica-Worms D, Baloh RH, Weihl CC, J Cell Biol 2009 187 875 888 10.1083/jcb.200908115 20008565
67. p47 is a cofactor for p97-mediated membrane fusion. Kondo H, Rabouille C, Newman R, Levine TP, Pappin D, Freemont P, Warren G, Nature 1997 388 75 78 10.1038/40411 9214505 (Pubitemid 27283891)
68. Cytosolic ATPases, p97 and NSF, are sufficient to mediate rapid membrane fusion. Otter-Nilsson M, Hendriks R, Pecheur-Huet EI, Hoekstra D, Nilsson T, EMBO J 1999 18 2074 2083 10.1093/emboj/18.8.2074 10205162 (Pubitemid 29179165)
69. Distinct AAA-ATPase p97 complexes function in discrete steps of nuclear assembly. Hetzer M, Meyer HH, Walther TC, Bilbao-Cortes D, Warren G, Mattaj IW, Nat Cell Biol 2001 3 1086 1091 10.1038/ncb1201-1086 11781570 (Pubitemid 33130459)
70. VCIP135, a novel essential factor for p97/p47-mediated membrane fusion, is required for Golgi and ER assembly in vivo. Uchiyama K, Jokitalo E, Kano F, Murata M, Zhang X, Canas B, Newman R, Rabouille C, Pappin D, Freemont P, Kondo H, J Cell Biol 2002 159 855 866 10.1083/jcb.200208112 12473691 (Pubitemid 36008367)
71. The localization and phosphorylation of p47 are important for Golgi disassembly-assembly during the cell cycle. Uchiyama K, Jokitalo E, Lindman M, Jackman M, Kano F, Murata M, Zhang X, Kondo H, J Cell Biol 2003 161 1067 1079 10.1083/jcb.200303048 12810701 (Pubitemid 36870169)
72. The maintenance of the endoplasmic reticulum network is regulated by p47, a cofactor of p97, through phosphorylation by cdc2 kinase. Kano F, Kondo H, Yamamoto A, Tanaka AR, Hosokawa N, Nagata K, Murata M, Genes Cells 2005 10 333 344 10.1111/j.1365-2443.2005.00837.x 15773896 (Pubitemid 40443685)
73. Morphogenesis of the endoplasmic reticulum: beyond active membrane expansion. Vedrenne C, Hauri HP, Traffic 2006 7 639 646 10.1111/j.1600-0854. 2006.00419.x 16683914 (Pubitemid 43676973)
74. Cdc48/p97 and Shp1/p47 regulate autophagosome biogenesis in concert with ubiquitin-like Atg8. Krick R, Bremer S, Welter E, Schlotterhose P, Muehe Y, Eskelinen EL, Thumm M, J Cell Biol 2010 190 965 973 10.1083/jcb.201002075 20855502
75. Vacuole-creating protein in neurodegenerative diseases in humans. Mizuno Y, Hori S, Kakizuka A, Okamoto K, Neurosci Lett 2003 343 77 80 10.1016/S0304-3940(03)00280-5 12759168 (Pubitemid 36577520)
76. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, Tu PH, Watts GD, Markesbery WR, Smith CD, Kimonis VE, J Neuropathol Exp Neurol 2006 65 571 581 10.1097/00005072-200606000-00005 16783167 (Pubitemid 44288941)
77. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1. Rumpf S, Lee SB, Jan LY, Jan YN, Development 2011 138 1153 1160 10.1242/dev.062703 21343367
78. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ, Curr Biol 2005 15 1961 1967 10.1016/j.cub.2005.09.043 16271875 (Pubitemid 41566145)
79. Lovastatin blocks N-ras oncogene-induced neuronal differentiation. Mendola CE, Backer JM, Cell Growth Differ 1990 1 499 502 2278880
80. Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. Sebti SM, Tkalcevic GT, Jani JP, Cancer Commun 1991 3 141 147 2043425
81. Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. Hering H, Lin CC, Sheng M, J Neurosci 2003 23 3262 3271 12716933 (Pubitemid 36531967)
82. Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. Cao J, Wang J, Qi W, Miao HH, Ge L, DeBose-Boyd RA, Tang JJ, Li BL, Song BL, Cell Metab 2007 6 115 128 10.1016/j.cmet.2007.07.002 17681147 (Pubitemid 47163620)
83. Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation. Leichner GS, Avner R, Harats D, Roitelman J, Mol Biol Cell 2009 20 3330 3341 10.1091/mbc.E08-09-0953 19458199
84. Sterol-induced dislocation of 3-hydroxy-3-methylglutaryl coenzyme A reductase from endoplasmic reticulum membranes into the cytosol through a subcellular compartment resembling lipid droplets. Hartman IZ, Liu P, Zehmer JK, Luby-Phelps K, Jo Y, Anderson RG, DeBose-Boyd RA, J Biol Chem 2010 285 19288 19298 10.1074/jbc.M110.134213 20406816